Sutro Biopharma, Inc. (STRO)
NASDAQ: STRO · Real-Time Price · USD
29.69
+2.31 (8.44%)
May 27, 2026, 4:00 PM EDT - Market closed
Sutro Biopharma Employees
Sutro Biopharma had 137 employees as of December 31, 2025. The number of employees decreased by 173 or -55.81% compared to the previous year.
Employees
137
Change
-173
Growth
-55.81%
Revenue / Employee
$727,066
Profits / Employee
-$1,121,182
Market Cap
491.90M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 137 | -173 | -55.81% |
| Sep 30, 2025 | 178 | -128 | -41.83% |
| Jun 30, 2025 | 244 | -60 | -19.74% |
| Mar 31, 2025 | 269 | -31 | -10.33% |
| Dec 31, 2024 | 310 | 8 | 2.65% |
| Sep 30, 2024 | 306 | 8 | 2.68% |
| Jun 30, 2024 | 304 | 7 | 2.36% |
| Mar 31, 2024 | 300 | 8 | 2.74% |
| Dec 31, 2023 | 302 | 24 | 8.63% |
| Sep 30, 2023 | 298 | 39 | 15.06% |
| Jun 30, 2023 | 297 | 55 | 22.73% |
| Mar 31, 2023 | 292 | 58 | 24.79% |
| Dec 31, 2022 | 278 | 54 | 24.11% |
| Sep 30, 2022 | 259 | 41 | 18.81% |
| Jun 30, 2022 | 242 | 38 | 18.63% |
| Mar 31, 2022 | 234 | 39 | 20.00% |
| Dec 31, 2021 | 224 | 33 | 17.28% |
| Sep 30, 2021 | 218 | 36 | 19.78% |
| Jun 30, 2021 | 204 | 27 | 15.25% |
| Mar 31, 2021 | 195 | 18 | 10.17% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Autolus Therapeutics | 754 |
| 4D Molecular Therapeutics | 196 |
| ADC Therapeutics | 193 |
| Neurogene | 131 |
| Ocugen | 116 |
| Adlai Nortye | 109 |
| Upstream Bio | 75 |
| Fulcrum Therapeutics | 55 |
STRO News
- 3 hours ago - Sutro Biopharma initiated with an Overweight at Barclays - TheFly
- 20 hours ago - Sutro Biopharma Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA - Transcripts
- 6 days ago - Sutro Biopharma price target raised to $10 from $9 at BofA - TheFly
- 13 days ago - Wedbush upgrades Sutro Biopharma to Outperform, raises price target to $60 - TheFly
- 13 days ago - Sutro Biopharma upgraded to Outperform from Neutral at Wedbush - TheFly
- 13 days ago - Sutro Biopharma price target raised to $50 from $28 at H.C. Wainwright - TheFly
- 13 days ago - Sutro Biopharma price target raised to $43 from $38 at Leerink - TheFly
- 13 days ago - Sutro Biopharma reports Q1 EPS ($2.94), consensus ($3.21) - TheFly